recent
studi
vilca
et
al
demonstr
burden
influenza
infect
pregnant
women
spain
bedsid
pointofcar
test
poct
allow
earlier
influenza
detect
treatment
though
perform
test
versu
cost
often
difficult
balanc
optim
costeffect
clinic
util
dear
editor
horn
et
al
recent
highlight
difficulti
obtain
accur
epidemiolog
data
hepat
e
viru
hev
infect
europ
may
partli
due
wide
spectrum
referr
rout
patient
diagnos
hev
infect
make
captur
data
across
differ
specialti
problemat
hepat
e
viru
nonenvelop
singlestrand
rna
viru
caus
acut
hepat
present
similar
way
hepat
fever
lethargi
fatigu
abdomin
pain
jaundic
four
common
genotyp
g
mainli
infect
man
infect
varieti
anim
howev
human
hev
infect
report
genotyp
like
hepat
transmit
via
faecalor
rout
tradit
associ
travel
hevendem
countri
howev
recent
year
hev
found
widespread
uk
swine
popul
relat
pork
product
sale
public
recent
recommend
routin
screen
hev
blood
organ
donor
increas
awar
hev
infect
may
also
caus
acut
hepat
differenti
diagnosi
particular
import
pregnant
women
hev
infect
caus
high
mortal
present
recent
diagnos
hev
case
differ
specialti
togeth
hev
sequenc
analysi
demonstr
varieti
referr
rout
infect
case
male
rheumatoid
arthriti
treatment
methotrex
admit
elderli
care
physician
histori
lethargi
weight
loss
painless
jaundic
admiss
liver
function
test
lft
alanin
transferas
alt
iul
alkalin
phosphatas
alp
iul
total
bilirubin
bil
discharg
work
diagnosi
methotrexateinduc
hepat
howev
subsequ
test
show
hev
igm
igg
posit
hev
rna
level
iuml
genotyp
closest
sequenc
similar
human
hev
infect
franc
fig
histori
recent
oversea
travel
case
male
hypertens
diabet
mellitu
dm
present
gener
practition
gp
abdomin
pain
jaundic
present
lft
alt
iul
alp
iul
bil
refer
hospit
oncal
surgic
team
admit
subsequ
test
show
hev
igm
igg
posit
hev
rna
level
iuml
genotyp
closest
sequenc
similar
hev
infect
wild
boar
germani
fig
histori
recent
foreign
travel
case
male
chronic
lymphocyt
lymphoma
admit
adult
haematolog
team
histori
mildli
elev
alt
month
presum
either
due
chemotherapi
lymphoma
develop
acut
lft
deterior
alt
iul
alp
iul
bil
subsequ
test
hev
igm
igg
posit
hev
rna
level
iuml
genotyp
closest
sequenc
similar
human
hev
infect
franc
fig
visit
scotland
preced
month
case
femal
type
dm
present
gp
week
histori
fatigu
epigastr
pain
loos
bowel
motion
lft
acut
derang
alt
iul
alp
iul
bil
test
found
hev
igm
equivoc
igg
neg
hev
rna
level
iuml
genotyp
closest
sequenc
similar
human
hev
infect
germani
fig
recent
travel
within
uk
case
old
femal
present
gp
histori
fatigu
abdomin
pain
jaundic
follow
diarrhoeal
ill
refer
hospit
medic
team
manag
outpati
admiss
lft
alt
iul
alp
iul
bil
follow
second
outpati
review
hev
serolog
request
show
hev
igm
igg
posit
hev
rna
level
iuml
genotyp
closest
sequenc
similar
human
hev
infect
japan
fig
arriv
uk
india
week
earlier
case
male
dm
depress
found
derang
lft
routin
gp
visit
alt
iul
alp
iul
bil
patient
purchas
testosteron
supplement
onlin
initi
diagnosi
druginduc
hepat
made
followup
hev
serolog
test
show
hev
igm
igg
posit
hev
rna
level
iuml
genotyp
closest
sequenc
similar
human
hev
infect
uk
fig
histori
recent
travel
hev
genotyp
patient
serum
plasma
hev
rna
amplifi
sequenc
subject
phylogenet
analysi
across
kb
region
open
read
frame
correspond
amino
acid
previous
describ
briefli
total
nucleic
acid
extract
serum
plasma
use
magna
pure
autom
extract
platform
roch
diagnost
ltd
burgess
hill
england
follow
cdna
creation
heminest
pcr
perform
sanger
sequenc
pcr
product
undertaken
use
beckman
sequenc
beckman
coulter
uk
ltd
wycomb
england
gener
sequenc
assembl
use
dnastar
version
lasergen
result
hev
sequenc
analysi
describ
fig
recent
introduct
routin
hev
screen
blood
organ
donor
uk
togeth
recognit
chronic
hev
infect
presenc
hev
food
product
gradual
increas
awar
hev
differenti
diagnosi
acut
hepat
demonstr
patient
describ
patient
eventu
diagnos
hev
infect
refer
varieti
clinic
specialti
elderli
care
surgic
haematolog
gp
ie
primari
care
often
incorrect
initi
delay
diagnosi
nonforeign
travelrel
hev
infect
case
genotyp
one
genotyp
case
infect
patient
recent
travel
hevendem
countri
genotyp
sequenc
accompani
refer
laboratori
comment
sequenc
highli
homolog
hev
sequenc
sporad
indigen
hepat
e
case
uk
demonstr
hev
genotyp
previous
mostli
associ
pig
european
wild
boar
predomin
caus
human
nontravelrel
hev
infect
uk
fortun
case
seri
also
show
increas
awar
hev
across
multipl
specialti
caus
acut
hepat
lead
increas
screen
improv
surveil
epidemiolog
data
better
understand
zoonot
infect
spread
human
popul
dear
editor
read
great
interest
articl
publish
journal
address
complex
interact
antimicrobi
stewardship
bacteri
drug
resist
sepsi
result
lay
press
coverag
topic
unit
kingdom
uk
current
oral
fluoroquinolon
extens
use
treat
wide
rang
bacteri
infect
mani
year
complic
sepsi
predomin
use
primari
care
set
concern
overus
drug
result
worsen
bacteri
resist
advers
drug
reaction
adr
increas
risk
clostridium
difficil
infect
focu
educ
intervent
clinician
public
policymak
earlier
trend
studi
involv
segment
popul
uk
report
provid
profil
fluoroquinolon
use
inconsist
result
detail
inform
type
fluoroquinolonerel
adr
therefor
aim
current
investig
better
defin
contemporari
trend
fluoroquinolon
use
provid
character
report
adr
larg
populationbas
investig
england
data
oral
antibiot
prescrib
commun
set
outsid
hospit
england
extract
prescript
cost
analysi
data
held
nh
digit
http
digitalnhsukdataandinform
publicationsstatisticalprescriptioncostanalysi
clinician
issu
prescript
includ
physician
nurs
practition
health
care
provid
includ
dentist
investig
focu
fluoroquinolon
conduct
data
oral
fluoroquinolon
includ
nation
yellow
card
interact
drug
analysi
profil
data
medicin
healthcar
product
regulatori
agenc
mhra
http
yellowcardmhragovukidap
interrog
data
extract
report
adr
fluoroquinolon
administ
oral
rout
administr
state
reaction
drug
administ
parenter
topic
rout
exclud
defin
rate
adr
adr
ratemillion
prescript
calcul
addit
investig
differ
organ
system
involv
adr
done
compar
purpos
among
differ
oral
fluoroquinolon
prescrib
studi
period
overal
six
million
prescript
oral
fluoroquinolon
issu
commun
set
eight
year
studi
period
ciprofloxacin
account
prescript
remark
declin
ciprofloxacin
prescript
period
declin
note
studi
year
fig
prescript
issu
oral
fluoroquinolon
also
declin
studi
period
except
levofloxacin
ofloxacin
prescript
increas
last
two
year
studi
everi
million
prescript
issu
studi
period
result
adr
design
nonseri
seriou
fatal
respect
ciprofloxacin
musculoskelet
reaction
frequent
report
seriou
reaction
n
tabl
tendon
disord
common
n
nervou
system
disord
next
frequent
report
seriou
reaction
n
paresthesiadysesthesiaperipher
neuropathi
common
n
follow
headach
n
seizur
n
fatal
ciprofloxacinrel
reaction
report
report
sudden
death
infect
attribut
c
difficil
infect
psychiatr
disord
result
suicid
previou
survey
england
yield
vari
result
like
due
part
variabl
healthcar
set
patient
cohort
includ
databas
previous
use
investig
exampl
one
larg
investig
n
acut
hospit
nation
health
servic
includ
data
im
health
data
warehous
fluoroquinolon
use
increas
notabl
larg
variat
data
comparison
individu
hospit
use
includ
rout
fluoroquinolon
administr
contrast
data
retriev
uk
thin
databas
includ
six
percent
uk
gener
practic
patient
popul
demonstr
reduct
fluoroquinolon
use
recent
year
inclus
communityprescrib
oral
fluoroquinolon
use
england
current
work
trend
analysi
like
accur
prior
report
respons
larg
postapprov
adr
serial
warn
releas
inform
clinician
patient
potenti
risk
fluoroquinolon
use
could
impact
fluoroquinolon
use
current
investig
along
educ
institut
intervent
although
uncommon
adr
chronic
result
disabl
effect
patient
suffer
diminish
qualiti
life
fluoroquinolon
use
associ
increas
risk
develop
c
difficil
infect
recurr
sever
complic
occur
includ
sepsi
death
latter
seen
current
investig
subject
nation
campaign
uk
reduc
use
fluoroquinolon
like
impact
trend
data
fluoroquinolon
use
describ
studi
develop
fluoroquinolon
resist
among
aerob
gramneg
bacilli
reduc
use
drug
class
could
contribut
trend
data
display
current
investig
interestingli
reduct
fluoroquinolon
burden
bacteria
seen
clinic
practic
improv
vitro
suscept
organ
describ
major
limit
work
inform
lack
unabl
identifi
causal
factor
respons
de
cline
use
oral
fluoroquinolon
communitybas
practic
england
cite
previous
use
yellow
card
system
identifi
adr
depend
passiv
report
bias
likelihood
nonsever
reaction
less
often
report
evidenc
data
present
current
survey
base
find
present
herein
mark
reduct
oral
fluoroquinolon
use
ambulatori
care
set
england
ciprofloxacin
account
bulk
use
report
seriou
adr
coupl
antimicrobi
stewardship
program
advoc
diminish
use
oral
fluoroquinolon
like
respons
declin
although
causeandeffect
evalu
fund
requir
data
use
investig
public
access
author
declar
conflict
interest
respiratori
viru
poct
becom
common
hospit
target
influenza
andor
respiratori
syncyti
viru
rsv
reliabl
posit
influenza
result
allow
infect
control
clinic
team
quickli
isol
treat
patient
discharg
patient
home
antivir
avoid
risk
infect
patient
staff
howev
unreli
test
ie
give
fals
influenza
positivefp
fals
negativefn
result
caus
lot
disrupt
patient
unnecessarili
isol
treat
basi
fp
result
nurs
share
bay
potenti
caus
outbreak
base
fn
result
henc
import
initi
choic
subsequ
perform
monitor
select
poct
throughout
season
use
influenza
nucleoprotein
np
antigenbas
bd
veritor
flu
b
test
becton
dickinson
uk
ltd
berkshir
england
adult
haematolog
bone
marrow
transplant
acut
chronic
includ
cystic
fibrosi
respiratori
gener
paediatr
includ
rsv
test
ward
clinic
team
left
use
test
patient
choic
depend
perceiv
clinic
infect
control
need
respiratori
swab
adult
viru
transport
medium
vtm
sigmavirocult
medic
wire
wiltshir
uk
nasopharyng
aspir
younger
children
collect
poct
residu
test
routin
virolog
laboratori
pcrbase
assay
respiratori
viru
panel
ausdiagnost
uk
ltd
chesham
uk
detect
influenza
ab
rsv
ab
enterorhinovirus
parainfluenza
virus
type
adenovirus
rhinovirus
coronavirus
human
metapneumovirus
poct
gold
standard
laboratori
result
compar
midseason
feb
endofseason
may
tabl
whilst
specif
influenza
b
rsv
remain
mostli
within
poct
kitspecifi
limit
across
patient
popul
sensit
vari
dramat
acut
respiratori
patient
influenza
sensit
influenza
b
throughout
season
indic
poct
laboratori
test
agre
posit
result
sampl
particularli
influenza
b
endofseason
poct
fp
fn
test
result
influenza
fp
fn
test
result
influenza
b
chronic
respiratori
patient
influenza
b
posit
result
agre
upon
poct
laboratori
test
henc
sensit
virus
endofseason
fp
fn
test
result
influenza
fp
fn
test
result
influenza
b
adult
haematolog
patient
influenza
patient
confirm
posit
poct
laboratori
test
sensit
midseason
addit
fn
poct
endofseason
sensit
influenza
b
posit
patient
confirm
either
test
sensit
overal
endofseason
fp
fn
influenza
fp
fn
influenza
b
best
overal
perform
poct
paediatr
popul
influenza
b
sensit
respect
fp
fn
influenza
fp
fn
influenza
b
rsv
sensit
within
rang
report
poct
kit
insert
fp
fn
previou
studi
publish
poct
report
higher
sensit
influenza
b
though
perform
test
vari
season
chang
circul
virus
fn
result
poct
like
due
low
viral
load
howev
caus
may
possibl
sampl
sequenc
part
routin
uk
surveil
respiratori
viru
unit
colindal
london
uk
limit
sequenc
analysi
show
presenc
influenza
np
mutat
patient
sampl
figur
though
none
also
test
poct
mutat
contribut
escap
npspecif
cytotox
lymphocyt
fact
among
oct
uk
influenza
sequenc
avail
influenza
sequenc
databas
global
initi
share
influenza
datagisaid
http
wwwgisaidorg
alreadi
acquir
np
mutat
compar
coincid
markedli
reduc
sensit
bd
veritor
test
seen
season
poctest
sampl
routin
sequenc
influenza
b
one
patient
sampl
contain
novel
np
mutat
figur
sequenc
download
databas
show
mutat
increas
proport
recent
oct
oct
potenti
impact
influenza
b
np
mutat
diagnost
assay
target
region
warrant
investig
howev
impact
individu
commerci
assay
difficult
assess
requir
proprietari
knowledg
assay
design
reason
fp
result
difficult
determin
may
due
occasion
transcript
error
poct
result
ward
staff
difficult
confirm
older
version
bd
veritor
test
kit
use
facil
record
result
oper
detail
electron
result
handwritten
ward
staff
result
book
kept
besid
poct
whatev
reason
poor
perform
poct
season
led
patient
fp
result
unnecessarili
treat
isol
other
fn
result
left
untreat
nurs
open
bay
potenti
caus
outbreak
result
experi
season
look
altern
sensit
specif
pcrbase
similar
molecular
detect
poct
late
duck
wave
chicken
wave
isol
wave
isol
wave
isol
wave
isol
wave
isol
addit
chicken
lineag
duck
also
harbor
virus
duck
lineag
isol
sinc
wave
isol
wave
isol
wave
isol
wave
isol
wave
isol
duck
lineag
virus
divers
ha
sequenc
share
ident
compar
chicken
lineag
ha
sequenc
share
ident
suggest
although
duck
major
host
duck
lineag
distant
virus
circul
duck
china
whether
virus
contribut
gene
chicken
rais
attent
virus
replic
effici
duck
howev
hpaiv
isol
duck
past
year
wave
system
replic
shed
viru
show
moder
pathogen
duck
new
find
suggest
duck
therefor
act
silent
carrier
aiv
would
make
control
influenza
virus
extrem
difficult
duck
rais
great
number
open
field
china
thu
mani
opportun
contact
domest
chicken
wild
bird
aquat
bird
natur
host
aiv
subtyp
thu
virus
extend
host
rang
duck
rais
concern
virus
might
circul
among
duck
chicken
wild
bird
lead
greatli
increas
divers
virus
inde
reassort
duck
aiv
novel
viru
detect
human
infect
novel
viru
found
decemb
dissemin
wild
bird
along
flyway
new
area
new
reassort
possibl
need
concern
thu
control
subtyp
duck
critic
need
evolut
ha
gene
virus
shown
clocklik
pattern
sinc
fig
b
suggest
ha
gene
sequenc
evolv
rel
constant
rate
time
bival
inactiv
vaccin
use
chicken
septemb
vaccin
mutat
ratio
signific
chang
seed
viru
vaccin
base
lpaiv
whether
accumul
genet
chang
time
lead
antigen
chang
need
monitor
vaccin
chicken
success
decreas
preval
virus
chicken
howev
face
new
challeng
rapidli
evolv
virus
due
circul
duck
genet
chang
measur
prevent
virus
continu
circul
duck
way
monitor
critic
detect
genet
chang
antigen
variant
virus
assess
effect
current
vaccin
dear
editor
read
interest
paper
heldt
colleagu
report
benefit
combin
multipl
biomark
test
includ
galactomannan
gm
elisa
assay
bronchoalveolar
lavag
fluid
balf
well
balf
aspergillu
specif
later
flow
devic
test
lfd
diagnosi
invas
pulmonari
aspergillosi
ipa
patient
hematolog
malign
importantli
earli
diagnosi
treatment
ipa
remain
import
factor
reduc
mortal
improv
outcom
import
limit
gm
test
limit
particular
vari
turnaround
time
day
center
depend
number
specimen
test
distancedur
transport
clinic
set
laboratori
test
perform
limit
part
overcom
newli
format
european
conform
ce
mark
aspergillu
specif
lfd
detect
extracellular
mannoprotein
antigen
secret
exclus
activ
growth
aspergillu
speci
via
jf
monoclon
antibodi
test
shown
increas
perform
diagnosi
ipa
use
combin
galactomannan
assay
recent
second
pointofcar
test
ipa
detect
galactomannan
develop
cemark
aspergillu
galactomannan
lfa
test
may
overcom
limit
long
turnaround
time
convent
galactomannan
elisa
test
may
facilit
pointofcar
diagnosi
ipa
object
studi
evalu
new
aspergillu
galactomannan
later
flow
assay
lfa
compar
perform
aspergillu
specif
lfd
biomark
diagnosi
ipa
patient
hematolog
malign
total
balf
sampl
obtain
patient
underli
hematolog
malign
patient
proven
ipa
patient
probabl
ipa
patient
possibl
ipa
two
patient
meet
mycolog
host
criteria
ipa
without
typic
radiolog
sign
defin
revis
european
organ
research
treatment
cancer
mycos
studi
group
eortcmsg
definit
eight
patient
fulfil
ipa
criteria
includ
analysi
ipa
classifi
accord
revis
eortcmsg
criteria
one
modif
exclus
betad
glucan
mycolog
criterion
balf
sampl
obtain
septemb
septemb
univers
california
san
diego
unit
state
gm
platelia
aspergillu
ag
elisa
biorad
laboratori
munich
germani
cultur
perform
prospect
balf
tabl
demograph
data
underli
diseas
studi
popul
evalu
first
time
newli
cemark
aspergillu
galactomannan
lfa
compar
perform
recent
cemark
aspergillu
specif
lfd
found
test
highli
sensit
specif
diagnos
ipa
patient
hematolog
malign
futur
studi
investig
diagnost
perform
pointofcar
test
larger
prospect
patient
cohort
hoenigl
receiv
research
grant
gilead
honoraria
research
practition
network
mycos
studi
group
r
taplitz
serv
merck
advisori
board
author
noth
declar
aspergillu
specif
lfd
provid
olm
diagnost
newcastl
upon
tyne
uk
aspergillu
galactomannan
lfa
provid
immi
norman
oklahoma
usa
neither
compani
role
studi
design
data
collect
analysi
interpret
decis
publish
write
manuscript
decis
submit
manuscript
public
